Mild cognitive impairment Mental and Behavioural Disorders Mild cognitive disorder
Conditions
Interventions
The supplements capsule is a standardised water extract of P.minor with a very high level of antioxidant properties and are a good source of natural antioxidants. A finished product in the form of ca
Sponsors
Biotropics Malaysia Berhad
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Malaysian older adults age between 60-75 years at the time of informed consent 2. BMI between 20-30 kg/m2 3. MCI based on Peterson criteria
Exclusion criteria
Exclusion criteria: 1. Alcohol and/or substance dependence 2. Had any type of neurodegenerative diseases (i.e. Parkinson disease, Alzheimer’s disease, dementia) 3. Had a diagnosis of a depressive disorder, schizophrenia or score > 5 in Geriatric Depression Scale (GDS) 4. Had any medical conditions might interfere with the subject’s participation in the trial (i.e. serious diabetes, chronic heart disease, cancer and kidney, liver or renal failure 5. Had Attention Deficit Hyperactivity Disorder (ADHD). These conditions might interfere with the outcome such as cognition function and psychosocial status 6. Regular consumer of traditional herbs, vitamin and mineral supplementation for the past six months because it will jeopardize the effect of supplement used in the study 7. Had a metallic implant, such as prostheses, shrapnel or aneurysm clips, or electronic implants, such as cardiac pacemakers 8. Claustrophobic 9. On Hormone Replacement Therapy (HRT)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function and mood state of older adults with MCI: 1. A series of neurocognitive tests (Mini Mental State of Examination, Digit Span, Rey Auditory Verbal Learning Test, Digit Symbol and Visual Reproduction) were used to assess global cognitive function, working and episodic memory, cognitive processing speed and visual memory of the participants 2. Their mood for the past seven days was also accessed using Profile of Mood State (POMS) questionnaire Measured at baseline, 3rd month and 6th month of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at baseline and 6th month of the study: 1. Oxidative stress markers (lipid hydroperoxide and malondialdehyde MDA), inflammation markers (inducible nitric oxide synthase iNOS and cyclooxygenase-2 COX-2), brain-derived neurotrophic factor (BDNF), blood glucose and lipid levels. The blood markers were analysed using ELISA method. 2. Brain activation examined via fMRI | — |
Countries
Malaysia
Contacts
Public ContactHuijin Lau
Outcome results
None listed